TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an announcement.
ImmuneOnco Biopharmaceuticals announced its unaudited consolidated interim results for the first half of 2025, highlighting significant progress in its oncology drug pipeline. The company completed patient enrollment and achieved primary endpoints in Phase II clinical trials for its core product, IMM01, in combination with azacitidine for treating higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, demonstrating promising efficacy and tolerability.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative oncology products. The company is engaged in advancing its drug pipeline, particularly in the area of cancer treatment, with a market focus on high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Average Trading Volume: 4,153,451
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.6B
See more insights into 1541 stock on TipRanks’ Stock Analysis page.